A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Doxorubicin; Doxorubicin liposomal; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Carcinoma; Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms NiCCC
- 30 Mar 2019 This trial has been discontinued in Denmark.
- 23 Mar 2019 This trial has been discontinued in Finland, according to European Clinical Trials Database.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology